Aevi Genomic Medicine, Inc., a clinical stage biopharmaceutical company, researches and develops novel therapies for pediatric onset and life-altering diseases in the United States. The company's lead product candidates include AEVI-001, a glutamatergic neuromodulator, which has completed Phase II/III SAGA trial for the treatment of a genetically-defined subset of adolescent attention deficit hyperactivity disorder patients who have genetic mutations that disrupt the mGluR network resulting in glutamate imbalance; and AEVI-002, an anti-LIGHT monoclonal antibody that is in Phase Ib clinical trial for use in severe pediatric onset Crohn's disease. The company also develops AEVI-005, which is in preclinical stage for the treatment of pediatric rare diseases. It has a strategic collaboration with Kyowa Hakko Kirin Co., Ltd. for an early stage monoclonal antibody program in an ultra-orphan pediatric indication. The company was formerly known as Medgenics, Inc. and changed its name to Aevi Genomic Medicine, Inc. in December 2016. Aevi Genomic Medicine, Inc. was founded in 2000 and is based in Wayne, Pennsylvania.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:GNMX
Previous SymbolNASDAQ:MDGN
CUSIPN/A
Phone610-254-4201
Debt
Debt-to-Equity RatioN/A
Current Ratio3.13
Quick Ratio3.13
Price-To-Earnings
Trailing P/E Ratio-1.51
Forward P/E Ratio-2.27
P/E GrowthN/A
Sales & Book Value
Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book Value$0.21 per share
Price / Book5.95
Profitability
EPS (Most Recent Fiscal Year)($0.83)
Net Income$-34,710,000.00
Net MarginsN/A
Return on Equity-152.07%
Return on Assets-122.06%
Miscellaneous
Employees17
Outstanding Shares64,770,000
Market Cap$84.20 million
OptionableOptionable
Aevi Genomic Medicine (NASDAQ:GNMX) Frequently Asked Questions
What is Aevi Genomic Medicine's stock symbol?
Aevi Genomic Medicine trades on the NASDAQ under the ticker symbol "GNMX."
How were Aevi Genomic Medicine's earnings last quarter?
Aevi Genomic Medicine Inc (NASDAQ:GNMX) issued its quarterly earnings results on Thursday, November, 1st. The biotechnology company reported ($0.12) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.15) by $0.03. View Aevi Genomic Medicine's Earnings History.
When is Aevi Genomic Medicine's next earnings date?
Has Aevi Genomic Medicine been receiving favorable news coverage?
News coverage about GNMX stock has trended negative recently, InfoTrie Sentiment reports. InfoTrie scores the sentiment of press coverage by reviewing more than six thousand news and blog sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores closest to five being the most favorable. Aevi Genomic Medicine earned a daily sentiment score of -2.6 on InfoTrie's scale. They also gave news headlines about the biotechnology company a news buzz of 7.0 out of 10, meaning that recent press coverage is likely to have an impact on the stock's share price in the next few days.
Who are some of Aevi Genomic Medicine's key competitors?
Some companies that are related to Aevi Genomic Medicine include LogicBio Therapeutics (LOGC), Krystal Biotech (KRYS), Cellular Biomedicine Group (CBMG), Sutro Biopharma (STRO), CASI Pharmaceuticals (CASI), Translate Bio (TBIO), ADMA Biologics (ADMA), Agenus (AGEN), Adverum Biotechnologies (ADVM), Idera Pharmaceuticals (IDRA), Surface Oncology (SURF), Nantkwest (NK), Neon Therapeutics (NTGN), Compugen (CGEN) and Allena Pharmaceuticals (ALNA).
Who are Aevi Genomic Medicine's key executives?
Aevi Genomic Medicine's management team includes the folowing people:
- Mr. Michael F. Cola, CEO, Pres & Director (Age 58)
- Mr. Brian D. Piper, CFO & Corp. Sec. (Age 46)
- Dr. Garry A. Neil, Chief Scientific Officer (Age 64)
- Ms. Colleen Anderson, VP of Clinical Operations
- Dr. Rick Couch, VP of Chemistry, Manufacturing & Controls
How do I buy shares of Aevi Genomic Medicine?
Shares of GNMX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Aevi Genomic Medicine's stock price today?
One share of GNMX stock can currently be purchased for approximately $1.25.
How big of a company is Aevi Genomic Medicine?
Aevi Genomic Medicine has a market capitalization of $84.20 million. The biotechnology company earns $-34,710,000.00 in net income (profit) each year or ($0.83) on an earnings per share basis. Aevi Genomic Medicine employs 17 workers across the globe.
What is Aevi Genomic Medicine's official website?
How can I contact Aevi Genomic Medicine?
Aevi Genomic Medicine's mailing address is 435 DEVON PARK DRIVE SUITE 715, WAYNE PA, 19087. The biotechnology company can be reached via phone at 610-254-4201 or via email at [email protected]
MarketBeat Community Rating for Aevi Genomic Medicine (NASDAQ GNMX)
MarketBeat's community ratings are surveys of what our community members think about Aevi Genomic Medicine and other stocks. Vote "Outperform" if you believe GNMX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe GNMX will underperform the S&P 500 over the long term. You may vote once every thirty days.
